Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IGLC2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IGLC2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IGLC2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IGLC2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IGLC2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/IGLC2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IGLC2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IGLC2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IGLC2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027682 | Cervix | N_HPV | immune response-regulating cell surface receptor signaling pathway | 22/534 | 315/18723 | 1.11e-04 | 2.18e-03 | 22 |
GO:005085111 | Cervix | N_HPV | antigen receptor-mediated signaling pathway | 17/534 | 240/18723 | 5.54e-04 | 7.40e-03 | 17 |
GO:00024551 | Cervix | N_HPV | humoral immune response mediated by circulating immunoglobulin | 11/534 | 121/18723 | 6.92e-04 | 8.86e-03 | 11 |
GO:00069581 | Cervix | N_HPV | complement activation, classical pathway | 10/534 | 108/18723 | 1.04e-03 | 1.21e-02 | 10 |
GO:00508641 | Cervix | N_HPV | regulation of B cell activation | 14/534 | 198/18723 | 1.69e-03 | 1.72e-02 | 14 |
GO:00024291 | Cervix | N_HPV | immune response-activating cell surface receptor signaling pathway | 18/534 | 291/18723 | 1.83e-03 | 1.82e-02 | 18 |
GO:00027571 | Cervix | N_HPV | immune response-activating signal transduction | 18/534 | 291/18723 | 1.83e-03 | 1.82e-02 | 18 |
GO:0008037 | Cervix | N_HPV | cell recognition | 15/534 | 225/18723 | 2.09e-03 | 2.00e-02 | 15 |
GO:00069092 | Cervix | N_HPV | phagocytosis | 17/534 | 308/18723 | 7.51e-03 | 4.88e-02 | 17 |
GO:00421131 | Cervix | N_HPV | B cell activation | 18/534 | 334/18723 | 7.67e-03 | 4.96e-02 | 18 |
GO:00027645 | Endometrium | AEH | immune response-regulating signaling pathway | 76/2100 | 468/18723 | 5.76e-04 | 5.71e-03 | 76 |
GO:000276412 | Endometrium | EEC | immune response-regulating signaling pathway | 80/2168 | 468/18723 | 2.20e-04 | 2.64e-03 | 80 |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
GO:00512517 | Oral cavity | EOLP | positive regulation of lymphocyte activation | 72/2218 | 362/18723 | 6.21e-06 | 1.22e-04 | 72 |
GO:00024292 | Oral cavity | EOLP | immune response-activating cell surface receptor signaling pathway | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00027572 | Oral cavity | EOLP | immune response-activating signal transduction | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00508677 | Oral cavity | EOLP | positive regulation of cell activation | 79/2218 | 420/18723 | 1.91e-05 | 3.02e-04 | 79 |
GO:00022534 | Oral cavity | EOLP | activation of immune response | 72/2218 | 375/18723 | 2.18e-05 | 3.35e-04 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGLC2 | SNV | Missense_Mutation | novel | c.22N>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
IGLC2 | SNV | Missense_Mutation | rs371508809 | c.151N>T | p.Ala51Val | p.A51V | | IG_C_gene | deleterious_low_confidence(0) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.130N>A | p.Ala44Glu | p.A44E | | IG_C_gene | deleterious_low_confidence(0) | benign(0.272) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
IGLC2 | SNV | Missense_Mutation | rs759610154 | c.280N>T | p.Ser94Ile | p.S94I | | IG_C_gene | deleterious_low_confidence(0) | benign(0.067) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.12N>A | p.Ala5Thr | p.A5T | | IG_C_gene | deleterious_low_confidence(0) | benign(0.027) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IGLC2 | SNV | Missense_Mutation | novel | c.226N>T | p.Pro76Leu | p.P76L | | IG_C_gene | deleterious_low_confidence(0) | possibly_damaging(0.494) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.177N>G | p.Lys60Glu | p.K60E | | IG_C_gene | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | rs755014029 | c.223N>T | p.Thr75Met | p.T75M | | IG_C_gene | deleterious_low_confidence(0) | benign(0.349) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.22C>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.136N>A | p.Ser46Asn | p.S46N | | IG_C_gene | deleterious_low_confidence(0) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |